T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan Inc
AGN
|
+$1.3B |
| 2 |
American Airlines Group
AAL
|
+$853M |
| 3 |
Intuitive Surgical
ISRG
|
+$816M |
| 4 |
Morgan Stanley
MS
|
+$681M |
| 5 |
Wynn Resorts
WYNN
|
+$622M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Procter & Gamble
PG
|
+$1.4B |
| 2 |
eBay
EBAY
|
+$763M |
| 3 |
DISCK
Discovery, Inc. Series C Common Stock
DISCK
|
+$760M |
| 4 |
Broadcom
AVGO
|
+$757M |
| 5 |
US Bancorp
USB
|
+$686M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 16.95% |
| 2 | Consumer Discretionary | 13.63% |
| 3 | Financials | 12.8% |
| 4 | Industrials | 12.27% |
| 5 | Technology | 9.96% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1176
Navigator Holdings
NVGS
$1.26B
| $16M | ﹤0.01% |
544,300
+313,940
| +136% | +$8.3M |
|
|
LLL
1177
DELISTED
L3 Technologies, Inc.
LLL
| $16M | ﹤0.01% |
132,439
-1,800
| -1% | -$214K |
|
|
QCOR
1178
DELISTED
QUESTCOR PHARMA INC
QCOR
| $16M | ﹤0.01% |
172,500
-89,300
| -34% | -$7.65M |
|
|
SUSS
1179
DELISTED
SUSSER HOLDINGS CORPORATION COMMON STOCK
SUSS
| $15.9M | ﹤0.01% |
197,200
+8,000
| +4% | +$592K |
|
|
GRA
1180
DELISTED
W.R. Grace & Co.
GRA
| $15.9M | ﹤0.01% |
167,790
+5,316
| +3% | +$501K |
|
1181
Hope Bancorp
HOPE
$1.83B
| $15.8M | ﹤0.01% |
992,380
-464,100
| -32% | -$7.35M |
|
|
CETV
1182
DELISTED
Central European Media Enterprises Ltd
CETV
| $15.7M | ﹤0.01% |
5,579,772
| – | – |
|
1183
Tyson Foods
TSN
$19.8B
| $15.7M | ﹤0.01% |
417,864
-9,610
| -2% | -$385K |
|
|
GWPH
1184
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| $15.6M | ﹤0.01% |
145,724
-153,115
| -51% | -$10.6M |
|
|
CADE
1185
DELISTED
Cadence Bank
CADE
| $15.6M | ﹤0.01% |
635,595
-54,100
| -8% | -$1.29M |
|
|
BID
1186
DELISTED
Sotheby's
BID
| $15.6M | ﹤0.01% |
371,436
+30,600
| +9% | +$1.25M |
|
|
WFC.WS
1187
DELISTED
Wells Fargo & Company Ws
WFC.WS
| $15.6M | ﹤0.01% |
726,775
| – | – |
|
1188
Travel + Leisure Co
TNL
$4.58B
| $15.6M | ﹤0.01% |
455,393
-11,075
| -2% | -$364K |
|
1189
Kopin
KOPN
$898M
| $15.6M | ﹤0.01% |
4,770,526
+122,156
| +3% | +$402K |
|
1190
MarineMax
HZO
$1.15B
| $15.5M | ﹤0.01% |
927,410
-388,760
| -30% | -$6.13M |
|
|
CLNY
1191
DELISTED
Colony Capital, Inc.
CLNY
| $15.5M | ﹤0.01% |
667,550
-56,180
| -8% | -$1.23M |
|
|
UTIW
1192
DELISTED
UTI WORLDWIDE INC
UTIW
| $15.5M | ﹤0.01% |
1,495,330
-45,550
| -3% | -$452K |
|
1193
PTC
PTC
$16.7B
| $15.4M | ﹤0.01% |
398,002
+37,989
| +11% | +$1.37M |
|
|
DXYN
1194
DELISTED
Dixie Group Inc
DXYN
| $15.3M | ﹤0.01% |
1,446,220
+219,500
| +18% | +$2.83M |
|
1195
U-Haul Holding Co
UHAL
$14.5B
| $15.3M | ﹤0.01% |
526,000
+50,000
| +11% | +$1.32M |
|
1196
Unum
UNM
$14.7B
| $15.3M | ﹤0.01% |
439,268
+29,900
| +7% | +$1.02M |
|
|
PETM
1197
DELISTED
PETSMART INC
PETM
| $15.2M | ﹤0.01% |
253,585
-16,300
| -6% | -$1.03M |
|
|
HPP
1198
Hudson Pacific Properties
HPP
$777M
| $15.1M | ﹤0.01% |
+85,391
| New | +$14.2M |
|
|
CMA
1199
DELISTED
Comerica
CMA
| $15.1M | ﹤0.01% |
300,231
+5,600
| +2% | +$273K |
|
1200
Fortune Brands Innovations
FBIN
$5.83B
| $15M | ﹤0.01% |
439,638
+12,003
| +3% | +$412K |
|
Similar funds
T. Rowe Price Associates's Q2 2014 Portfolio in Review
As of Q2 2014, T. Rowe Price Associates held 2,596 positions worth $463B, up 3.9% from $445B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
T. Rowe Price Associates's Q2 2014 filing shows 97 new, 1,091 increased, 793 reduced and 67 closed positions. Its largest new stake was Teva Pharmaceuticals: 4,638,481 shares worth $243M. The largest sale was Procter & Gamble, an estimated $1.4B.
By sector, the portfolio is most concentrated in Healthcare at 17% of assets, up from 16% a quarter earlier, followed by Consumer Discretionary and Financials.
- T. Rowe Price Associates's largest Q2 2014 buy was Teva Pharmaceuticals: 4,638,481 shares worth $243M.
- T. Rowe Price Associates added most to Allergan Inc in Q2 2014, an estimated $1.3B increase.
- T. Rowe Price Associates's biggest Q2 2014 reduction was Procter & Gamble, cutting an estimated $1.4B.
- T. Rowe Price Associates fully exited Santander in Q2 2014, selling an estimated $134M.
- T. Rowe Price Associates's ten largest holdings make up 12% of its $463B portfolio in Q2 2014.
- T. Rowe Price Associates opened 97 new positions and closed 67 in Q2 2014.
- T. Rowe Price Associates's portfolio value rose 3.9% quarter-over-quarter to $463B.
Based on T. Rowe Price Associates's 13F filing for Q2 2014, filed 14 Aug 2014.